IP Verse

Stable Semaglutide Compositions And Uses Thereof

Patent No. EP3870213 (titled "Stable Semaglutide Compositions And Uses Thereof") was filed by Novo Nordisk on Oct 25, 2019. The application was issued on Jun 7, 2023.

Patent Summary

Liquid pharmaceutical compositions containing GLP-1 peptide semaglutide with improved stability for subcutaneous injection. The compositions contain semaglutide, an isotonic agent, and histidine. The histidine concentration is 0.5-100 mM and the pH is 6.0-10.0. The histidine stabilizes the semaglutide in the liquid formulation by reducing impurities like high molecular weight proteins and hydrophobic impurities during storage. The stabilized liquid compositions can be used in prefilled syringes or cartridges for convenient subcutaneous injection.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMar 7, 2024TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3870213

NOVO NORDISK
Application Number
EP19801228A
Filing Date
Oct 25, 2019
Status
Granted And Under Opposition
May 5, 2023
Publication Date
Jun 7, 2023
External Links
Slate, Register , Google Patents